Work

Abstract A015: AB801, a potent and selective clinical-stage AXL inhibitor, enhances the anti-tumor efficacy and duration of response of KRAS inhibitors

Year: 2026

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.rasoncother26-a015

Authors: Ester Fernandez-Salas, Susan L. Paprcka, Jhansi L. Leslie, Tiffany Huang, Logan Chinn, Jenna Pappalardo, Umida Djakbarova, Dillon H. Miles, Ruben Flores, Gonzalo Barajas, Matt Wright

Institution: Arcus Biosciences (United States)

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7133808131

Cites:

Cited by:

Related to: